Back to search

University of British Columbia

Combining DNA-PK inhibitors with DNA-damaging therapies expands the targeted cell population to kill more cancer cells but also elevates toxicities in normal cells

Abstract

dc:description

Inhibition of DNA-PK disrupts the repair of DNA double strand breaks (DSBs) through non-homologous end-joining (NHEJ), making tumour cells more susceptible to DNA-damaging agents. This thesis explores the underlying mechanisms as well as target cell populations of DNA damaging agents when they are combined with DNA-PK inhibitors, particularly Topoisomerase II (Top2) poisons and radiotherapy. The results confirmed that DNA-PK inhibitors + Top2 poisons is a potent combination that increased the cell kill both in vitro and in vivo. Flow cytometry and immunofluorescent staining results further showed amplified DNA damage not only in the proliferating cells, but also in non-proliferative though transcriptionally active cells. This broadening of the target population of a DNA-damaging anti-cancer treatment by DNA-PK inhibitors was also seen with radiation in breast cancer type 1 or type 2 susceptibility protein (BRCA1/2) deficient tumour cells. In vitro and in vivo evaluation of cell survival both demonstrated greater radiosensitizing effects of DNA-PK inhibitors in BRCA1/2 deficient cells relative to a Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor that has a well-established synthetic lethal effect in these cells. Compared with the PARP inhibitor, DNA-PK inhibitors have a greater anti-cancer effect due to their wider scope of activity, sensitizing both proliferating and non-proliferating tumour cells to radiation treatment. However, the targeting of non-proliferating cells with DNA-PK inhibitors also posed a significant survival challenge to normal tissue cells, as increased in vivo toxicity was observed in the treatment groups for both Top2 poisons and radiation treatment when combined with DNA-PK inhibitors. These findings demonstrate the importance of validating target cell population of anti-cancer treatments, including for novel combinations when the affected cells and activity mechanisms for individual treatments might already be established. The implications are significant for DNA-PK inhibitors, already in clinical trials in combination with Top2 poisons and radiation where dose-limiting toxicity has already limited the scope of clinical benefit. The moderate to severe toxicity observed in mice treated with DNA damaging agents in combination with DNA-PK inhibitors suggests that a tumour-specific targeting strategy and careful dosage design is required to minimize adverse effects in normal tissues and achieve clinical benefits.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Interdisciplinary Oncology
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Wang, Taixiang
Contributors dc:contributor
  • Minchinton, Andrew

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/88125

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Wang, Taixiang. Combining DNA-PK inhibitors with DNA-damaging therapies expands the targeted cell population to kill more cancer cells but also elevates toxicities in normal cells. doctoral thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/88125